Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOBAL LEADERS: Anti-platelet Therapy After Stent Implantation
NCT01813435Phase 3Completed
- Sponsor
- ECRI
- Start
- Jul 2013
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of ticagrelor in coronary artery disease (CAD) (2 arms), sponsored by ECRI. Primary endpoint: Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction at 2 years. Started Jul 2013; status: completed.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01813435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813435.